Recurrence-free survival was numerically higher with adjuvant pembrolizumab, but difference was ...
Median duration of recurrence-free survival was 61.1 months with nivolumab and ...
Findings seen among both those previously treated for cancer and cancer-naive ...
Suggestive increases for prostate and colorectal cancer mortality observed with more ...